Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with…
<!-- Name:DistributionId Value:8841838 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4570 -->…
Browsing Tag
Kapruvia
Kapruvia® approved in Switzerland with additional regulatory decisions expected in H2 2022
Kapruvia® (difelikefalin) is the first and only therapy approved through consortium filing for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patients Therapy recently approved in Canada under the…
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in…
First approved therapy in Europe for the treatment of chronic kidney disease (CKD)-associated pruritus in hemodialysis patientsFirst launches in Europe expected in H2 2022 ST. GALLEN, Switzerland and STAMFORD, Conn., April 28, 2022…
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in…
Committee for Medicinal Products for Human Use (CHMP) recommends approval of Kapruvia® (difelikefalin) as first therapy in Europe for the treatment of chronic kidney disease associated-pruritus (CKD-aP) in hemodialysis patientsEuropean…